<DOC>
	<DOC>NCT01605825</DOC>
	<brief_summary>This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.</brief_summary>
	<brief_title>A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>History of a stable sensorimotor deficit due to an ischemic stroke, as confirmed by the Investigator with supportive prior imaging findings (MRI/ CT scan) ≥ 6 months poststroke Have a body mass index (BMI) ranging between 18.0 35.0 kg/m,2 inclusive Stable concomitant medication therapy regimen within 4 weeks of screening visit History of seizures, except simple febrile seizures Moderate or severe renal impairment as defined by a calculated creatinine clearance of ≤ 50 mL/minute using the CockcroftGault Equation Botulinum toxin use within 2 months prior to the Screening Visit Orthopedic surgical procedures in any of the extremities within the past 6 months Diagnosis of multiple sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>